Highest-materiality recent filing
Fennec announces new PEDMARK data at ASCO showing hearing loss reduction in pediatric/AYA patients
Phase 2/3 STS-J01 study met primary endpoint: hearing loss 16-24% vs 56-63% historical control.
Fennec grants 50,000 stock options to three new employees as inducement awards
Options exercisable at $9.75/share, 10-year term, vest over 3 years (1/3 on first anniversary, then monthly over 24 months).
Fennec board member Raykov retiring; board reduced to 5 directors
Rostislav Raykov notified company on Apr 27, 2026, of retirement from Board.
Fennec announces four PEDMARK abstracts accepted at 2026 ASCO meeting
Four abstracts evaluating PEDMARK accepted for presentation/publication at the 2026 ASCO Annual Meeting (May 29–June 2, Chicago).
Phase I/II study by University of Arizona Cancer Center to evaluate PEDMARK for preventing cisplatin-induced ototoxicity in head and neck and testicular cancer patients.
Fennec posts record FY2025 PEDMARK sales $44.6M (+50% YoY); Q4 $13.8M (+75%)
Full-year net product sales $44.6M vs $29.6M in 2024; Q4 $13.8M vs $7.9M in prior year.
Fennec settles PEDMARK patent litigation; Cipla barred from generic until 2033
Lawsuit dismissed; each party bears its own costs.
Fennec announces TGH Cancer Institute study of PEDMARK for ototoxicity in AYA and adult patients
Tampa General Hospital Cancer Institute initiates real-world study of PEDMARK (sodium thiosulfate) to reduce ototoxicity risk in AYA and adult patients receiving cisplatin.
Data from retrospective review of 15 adult HNC patients presented at 2026 MHNCS symposium (Feb 19-21).
Fennec announces City of Hope IST testing PEDMARK in adult testicular germ cell tumors
Phase I study (NCT07218913) evaluating PEDMARK to prevent cisplatin-induced ototoxicity in adults with stage II-III metastatic testicular germ cell tumors.
Primary endpoint met: hearing loss in 24% (ASHA) and 16% (Brock) of evaluable patients vs 56-63% historically.
Fennec Pharmaceuticals redeems all convertible notes, now debt-free
Redeemed all remaining Petrichor convertible notes for $21.73M (principal $19.48M, accrued interest $305k, redemption fee $1.95M).
Fennec raises $5.025M in Canadian private placement, redeems $21.7M Petrichor notes
Issued 670,000 common shares at US$7.50 per share for gross proceeds of $5,025,000 from existing institutional shareholders in Canada (excl. Quebec).
Fennec prices $35M public offering of 4.7M shares at $7.50/share to repay debt
Offering of 4,666,667 common shares at $7.50 per share; gross proceeds ~$35M.
All six director nominees elected; votes for each exceeded 13.2M versus under 1M withheld.
Fennec Pharma reports FY2024 PEDMARK sales $29.6M (+40% YoY); Q4 EBITDA loss $0.6M, cash $26.6M
FY2024 net product sales $29.6M, up 40% from $21.3M in 2023; net loss narrowed to $0.07M from $16.0M.
Fennec's partner Norgine launches PEDMARQSI in Germany for cisplatin-induced hearing loss prevention
PEDMARQSI (sodium thiosulfate injection) launched in Germany by Norgine for prevention of ototoxicity in pediatric patients.
Fennec repays $13M convertible debt; eliminates $1.5M annual interest
Repurchased and redeemed $13M of convertible notes on Dec 18, 2024; fully retires First and Third Closing Notes.
NICE issued positive final draft guidance recommending PEDMARQSI for prevention of cisplatin-induced hearing loss in patients aged 1 month-17 years with localized solid tumors.
Fennec Pharma appoints new CMO, CCO, CSO to accelerate growth
Pierre Sayad appointed CMO, Terry Evans CCO, Christiana Cioffi CSO, effective Oct. 28, 2024.
Fennec appoints Jeffrey Hackman as CEO, succeeding Rostislav Raykov
Hackman named CEO and director effective August 16, 2024; Raykov steps down after 15 years, remains on board.
Fennec COO Adrian Haigh departs; 66,667 options accelerated at $8.03
Adrian Haigh left COO role effective June 30, 2024; joined as COO Aug 2023 after nine years as independent director.
Fennec shareholders approve all proposals at 2024 annual meeting
Five director nominees elected: Khalid Islam, Rallis, Brughera, Cook, Raykov.
Fennec Pharma to report Q1 2024 results on May 14; conference call at 8:30am ET
First quarter 2024 financial results to be released before U.S. market open on Tuesday, May 14, 2024.
Fennec Pharma FY2023 PEDMARK sales $21.3M, Q4 net loss $2.7M; $43M licensing deal bolsters cash
FY2023 PEDMARK net product sales $21.3M (vs $1.5M in 2022); Q4 net sales $9.7M.
Fennec licenses PEDMARQSI to Norgine for EU/AU/NZ; €40M upfront, up to €210M milestones
Exclusive license covers Europe (incl. UK), Australia, New Zealand; Norgine to commercialize.
Fennec pre-announces Q4 2023 net revenue ~$9.2-9.7M, up 41-49% QoQ
Q4 2023 net revenue expected $9.2-9.7M, a 41-49% increase vs Q3 2023.
Fennec prelim Q4 2023 net revenue $9.2-9.7M (+41-49% QoQ); FY 2023 $20.7-21.2M
Q4 2023 net revenue expected $9.2-9.7M, up 41-49% from Q3 2023.
FDA reminds providers PEDMARK is not substitutable with other STS products
FDA publicly warned healthcare providers that PEDMARK (sodium thiosulfate injection) must not be substituted with other STS products.
Closed third tranche of $5M senior secured convertible notes under existing SPA with Petrichor.
Fennec Q3 2023: PEDMARK revenue $6.5M (+96% QoQ); UK approval for PEDMARQSI
PEDMARK net product revenue $6.5M in Q3 2023, up 96% from $3.3M in Q2 2023.
On April 27, 2026, Rostislav Raykov notified Fennec Pharmaceuticals Inc. (the "Company") of his desire to retire from the Company's Board of Directors (the "Board") and that he will not stand for re-election at the Company's 2026 annual meeting of shareholders (the "Annual Meeting").
Ms. Christiana Cioffi, MBA, as Chief Strategy Officer ("CSO"),
On October 28, 2024, Fennec Pharmaceuticals Inc.'s (the "Company") announced the appointments of Mr. Pierre S. Sayad, PhD, M.S., as Chief Medical Officer ("CMO"),
Mr. Terry Evans as Chief Commercial Officer ("CCO"),
the Company announced the departure of Rostislav Raykov from his position as the Company’s Chief Executive Officer
the Company announced the appointment of Jeffrey S. Hackman as CEO and a member of the Board.
the Company announced the appointment of Jeffrey S. Hackman as CEO and a member of the Board.
On June 30, 2024, Adrian Haigh departed from his position as Fennec Pharmaceuticals Inc.’s (the "Company") Chief Operating Officer
Max materiality 0.85 · Median 0.65 · Most common event other_material